ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VOR Vor Biopharma Inc

1.61
-0.105 (-6.12%)
Last Updated: 19:59:11
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vor Biopharma Inc NASDAQ:VOR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.105 -6.12% 1.61 1.61 1.62 1.73 1.54 1.72 312,499 19:59:11

Vor Bio to Participate in Upcoming Investor Conferences

30/08/2023 1:00pm

GlobeNewswire Inc.


Vor Biopharma (NASDAQ:VOR)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Vor Biopharma Charts.

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Citi’s 2023 18th Annual BioPharma Conference1x1 Investor Meetings: Thursday, September 7, 2023 Location: Four Seasons Hotel, Boston, MA

H.C. Wainwright 25th Annual Global Investment Conference (Hybrid)Virtual Presentation: Monday, September 11, 2023 Location: Lotte New York Palace Hotel, New York, NY

Baird’s 2023 Global Healthcare Conference Presentation: Wednesday, September 13, 2023 at 9:05 am ETLocation: Intercontinental New York Barclay, New York, NY

Morgan Stanley 21st Annual Global Healthcare ConferenceFireside Chat: Wednesday, September 13, 2023 at 4:15 pm ETLocation: Sheraton Hotel, New York, NY

Live webcasts and archived replays of the presentation at the H.C. Wainwright 25th Annual Global Investment Conference and the fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference will be available on the investors section of www.vorbio.com.

About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & InvestorsSarah Spencer +1 857-242-6076sspencer@vorbio.com

1 Year Vor Biopharma Chart

1 Year Vor Biopharma Chart

1 Month Vor Biopharma Chart

1 Month Vor Biopharma Chart